Verification evidence is still being completed.
PDF / print export
STipe Therapeutics ApS
Aarhus, Denmark
- Verified lead
- Claus Elsborg Olesen
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Co-Founder and Chief Executive Officer
- 2026 technical specialization
- Immuno-Oncology, STING-Pathway Priming, and Preclinical Small-Molecule Discovery
- Review cycle
- 24 April 2026
- Full address
- Inge Lehmanns Gade 10, 8000 Aarhus C, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- STipe Therapeutics About page naming Claus Elsborg Olesen as Co-Founder and CEO.
- Editorial note
- Aarhus preclinical immuno-oncology biotech with named co-founder CEO, STING-pathway priming platform, and 20 million EUR 2019 Series A financing on record.
Immuno-Oncology, STING-Pathway Priming, and Preclinical Small-Molecule Discovery
Public CEO disclosure on company site, The Org corporate profile, 2019 Series A financing documentation
Aarhus preclinical immuno-oncology biotech with named co-founder CEO, STING-pathway priming platform, and 20 million EUR 2019 Series A financing on record.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Aarhus, Denmark
STipe Therapeutics ApS
Immuno-Oncology, STING-Pathway Priming, and Preclinical Small-Molecule Discovery · Preclinical small-molecule development
Aarhus preclinical immuno-oncology biotech with named co-founder CEO, STING-pathway priming platform, and 20 million EUR 2019 Series A financing on record.
- Lead
- Claus Elsborg Olesen (verified ↗)
- Address
- Inge Lehmanns Gade 10, 8000 Aarhus C, Denmark (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical small-molecule development
- Capabilities
- STING-Pathway Priming Small-Molecule Discovery · Immuno-Oncology Lead Programs · Tumor Microenvironment Modulation
- Founded
- 2019
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Claus Elsborg Olesen
Co-Founder and Chief Executive Officer
Full addressInge Lehmanns Gade 10, 8000 Aarhus C, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
B2BHint Denmark business directory (CVR 39691175) listing STipe Therapeutics at Inge Lehmanns Gade 10.
Open sourcePreclinical small-molecule development
Aarhus, Denmark. Immuno-Oncology, STING-Pathway Priming, and Preclinical Small-Molecule Discovery. Review completed on 24 Apr 2026.
Danish Medicines Agency and EMA for future clinical development
Public CEO disclosure on company site, The Org corporate profile, 2019 Series A financing documentation
Immuno-Oncology, STING-Pathway Priming, and Preclinical Small-Molecule Discovery
Aarhus preclinical immuno-oncology biotech with named co-founder CEO, STING-pathway priming platform, and 20 million EUR 2019 Series A financing on record.
Editorial note
STipe Therapeutics is an Aarhus preclinical immuno-oncology biotech with a named co-founder CEO, a STING-pathway priming platform, and a 20 million EUR 2019 Series A financing on record.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
STING-Pathway Priming Small-Molecule Discovery
Immuno-Oncology Lead Programs
Tumor Microenvironment Modulation
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
STING-pathway assays
Small-molecule discovery workflow
Immuno-oncology disease models
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is STipe Therapeutics ApS located?
- STipe Therapeutics ApS operates from Inge Lehmanns Gade 10, 8000 Aarhus C, Denmark, Aarhus, Denmark.
- Who runs STipe Therapeutics ApS?
- STipe Therapeutics ApS is led by Claus Elsborg Olesen, Co-Founder and Chief Executive Officer. Verified 24 Apr 2026.
- What does STipe Therapeutics ApS do?
- Aarhus preclinical immuno-oncology biotech with named co-founder CEO, STING-pathway priming platform, and 20 million EUR 2019 Series A financing on record. Core capabilities: STING-Pathway Priming Small-Molecule Discovery, Immuno-Oncology Lead Programs, Tumor Microenvironment Modulation.
Editorial context
Related technical briefs
Briefs that name Aarhus as a covered market or city.